Applications

1221 – Transurethral Injection of Botulinum Toxin into the Bladder Wall for Urinary Incontinence due to Neurogenic Detrusor Overactivity

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

-

Service or technology in this application

The patient may be given a local anaesthetic with or without sedation, or general anaesthesia, prior to the procedure. A rigid or flexible cystoscope is inserted through the urethra and into the bladder to allow visualisation of the bladder wall. Reconstituted Botox? (200U in 30ml) is then injected into the inner muscular layer of the bladder wall.

Medical condition this application addresses

Urinary incontinence due to neurogenic overactive bladder (NOAB) also called neurogenic detrusor overactivity (NDO) is a distinct subset of the overactive bladder (OAB) syndrome that arises either as a direct result of a primary neurologic disorder (such as multiple sclerosis) or spinal cord injury or secondary to a non-neurologic disease impacting the bladder’s neural pathway.

Application documents

PICO confirmation

Public summary document – November 2012

Public summary document – April 2013

Predicted versus actual

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 
    • 1 - 2 December 2011
  • ESC meeting:
    • 11 - 12 October 2012
  • MSAC meeting: 
    • 29 - 30 November 2012
    • 5 April 2013
    • 24 - 25 November 2016